EP0118891A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Monoclonal antibodies to human bladder and ureter cancers and method
Assignee: Memorial Sloan Kettering Cancer Center
•
Filing: 1984-03-08
•
Granted: —
•
Expires: 2004-03-08
Abstract
Abstract A panel of monoclonal antibodies, produced from human bladder tumors as immunogen, is used to diagnose the presence of transitional cell carcinoma in patients. The panel is also used to identify and differentiate low grade non-invasive papillomasfrom invasive life-threatining transitional cell carcinomas, thereby enabling decisions as to the extent of bladder surgery. These mAbs can also be used as a panel for tissue typing of normal and abnormal cell specimens.
Inventors
- 👤 Yves Fradet
- 👤 Carlos Cordon-Cardo
- 👤 Willet F. Whitmore, Jr.
- 👤 Myron R. Melamed
- 👤 Lloyd J. Old
- 👤 Kenneth O. Lloyd
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-06 02:06
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3038; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/863; Y10S530/864
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
32 words
A panel of two or more monoclonal antibodies recognizing human bladder transitional cells selected from the group consisting of T16, T23, J233, JP165, T101 Om37, Om5, T43, J143, T87, T138 and T110.
Claim 2
Dependent Claim
32 words
A panel of two or more monoclonal antibodies recognizing human bladder transitional cells selected from the group consisting of T16, T23, J233, JP165, T101 Om37, Om5, T43, J143, T87, T138 and T110.
Claim 3
Dependent Claim
20 words
Monoclonal antibodies of Claim 1 recognizing human bladder transitional epithelial antigens selected from the group of glycoproteins, glycolipids and proteins.
Claim 4
Dependent Claim
15 words
Monoclonal antibodies of Claim 2 wherein the glycoprotein molecular weight range is approximately 25-240 kd.
Claim 5
Dependent Claim
36 words
Monoclonal antibodies of claim 3 wherein the glycoprotein antigens are selcted from the molecular weight group consisting of 4C kd, 85 kd, 60 kd, 80 kd, 30 kd, 120 kd, 25 kd, 140 kd, 240 kd.
Claim 6
Dependent Claim
36 words
Antibody producing hybridoma cell line characterized by the production of monoclonal antibodies recognizing human bladder transitional cells selected from the group consisting of T16, T23, J233, JP165, T101 Om37, Om5, T43, J143, T87, T138 and T110.
Claim 7
Dependent Claim
36 words
Antibody producing hybridoma cell line characterized by the production of monoclonal antibodies recognizing human bladder transitional cells selected from the group consisting of T16, T23, J233, JP165, T101 Om37, Om5, T43, J143, T87, T138 and T110.
Claim 8
Dependent Claim
38 words
Monoclonal antibody producing hybridoma cell line of Claim 5 formed by fusing a myeloma derived cell strain and spleen cells derived from a mammal immunized with established culture lines of human bladder transitional cell carcinomas or human papilloma.
Claim 9
Dependent Claim
42 words
Method of forming a monoclonal antibody producing hybridoma cell line of claim 6 which comprises fusing a myeloma derived cell strain with spleno- cytes derived from a mammal immunized with established culture lines of human bladder transitional cell carcinoma or hyman papilloma.
Claim 10
Dependent Claim
10 words
Hybridoma cell line formed by the method of Claim 7.
Claim 11
Dependent Claim
11 words
Monoclonal antibodies produced by the hybridoma cell line of Claim 8.
Claim 12
Dependent Claim
50 words
Method for differentiating between normal and malignant human bladder cells which comprises contacting a human bladder cell specimen with a monoclonal antibody selected from the group consisting of T16, T23, J233, JP165, T101 Om37, Om5, T43,, J143, T87, T138 and T110 and detecting malignant bladder cells reacting with said antibody.
Claim 13
Dependent Claim
50 words
Method for differentiating between normal and malignant human bladder cells which comprises contacting a human bladder cell specimen with a monoclonal antibody selected from the group consisting of T16, T23, J233, JP165, T101 Om37, Om5, T43,, J143, T87, T138 and T110 and detecting malignant bladder cells reacting with said antibody.
Claim 14
Dependent Claim
26 words
Method of Claim 10 wherein said specimen is separately contacted with a panel of two or more of said monoclonal antibodies each of which is different.
Claim 15
Dependent Claim
51 words
Method for differential diagnosis of malignant human bladder transitional cells which comprises contacting a human bladder transitional cell specimen with a monoclonal antibody selected from a group of T16, T23, J233, JP165, T101 Om37, Om5, T43, J143, T87, T138 and T110 and detecting malignant transitional bladder cells reacting with said antibody.
Claim 16
Dependent Claim
51 words
Method for differential diagnosis of malignant human bladder transitional cells which comprises contacting a human bladder transitional cell specimen with a monoclonal antibody selected from a group of T16, T23, J233, JP165, T101 Om37, Om5, T43, J143, T87, T138 and T110 and detecting malignant transitional bladder cells reacting with said antibody.
Claim 17
Dependent Claim
11 words
Method of Claim 12 wherein the detection method is flow cytometry.
Claim 18
Dependent Claim
26 words
Method of Claim 12 wherein said specimen is separately contracted with a panel of two or more of said monoclonal antibodies each of which is different.
Claim 19
Dependent Claim
27 words
Method of Claim 12 wherein non-invasive tumors are distinguished from invasive transitional cell carcinomas using monoclonal antibody selected from the group consisting of Om5, Om37 and T43.
Claim 20
Dependent Claim
28 words
Method of Claim 12 wherein transitional cell carcinomas are distinguished from bladder sarcomas using monoclonal antibodies selected from the group consisting of Om37, T16, T87, J143 and T43.
Claim 21
Dependent Claim
10 words
Monoclonal antibodies of Claim 1 reacted with human bladder cells.
Claim 22
Dependent Claim
12 words
Monoclonal antibodies of Claim 1 reacted with human bladder cell antigenic components.
Claim 23
Dependent Claim
35 words
Method of classifying human cells which comprises contacting a human tissue or cell specimen with each of the monoclonal antibodies from the panel of monoclonal antibodies of claim 1, and observing a positive immunological response.
Claim 24
Dependent Claim
10 words
Monoclonal antibody T110 recognizing human bladder transitional cell shed antigen.
Claim 25
Dependent Claim
10 words
Monoclonal antibody T110 recognizing human bladder transitional cell shed antigen.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.